bioengineer.org /3 weeks ago

Rare EGFR Mutation Shows Primary Resistance to Afatinib in Lung Cancer Case

A case report documents rapid progression and death in a lung cancer patient with a rare EGFR PACC mutation who showed primary resistance to afatinib.

Read source
qchron.com /4 weeks ago

RYBREVANT FASPROâ„¢ (amivantamab and hyaluronidase-lpuj) combination demonstrates 77% overall response rate in first-lin...

Responses were deep and durable, with 65% ongoing at clinical cutoffResults support continued evaluation of the investigational RYBREVANT FASPRO regimen in the ongoing first-line P...

Read source
qchron.com /4 weeks ago

New data on Lilly's investigational treatment olomorasib at ESMO 2026 show durable first-line activity in KRAS G12C-muta...

Data presented at ESMO highlight the promising efficacy of olomorasib in combination with standard-of-care immunotherapy with or without chemotherapy in first-line advanced KRAS G1...

Read source
bioengineer.org /1 week ago

Patient Survived Twenty Months After Small-Cell Transformation of Resected Lung Adenocarcinoma

A clinical case report documents a 48-year-old woman with EGFR-mutant lung adenocarcinoma who developed small-cell lung cancer transformation four years after surgery and survived...

Read source
qchron.com /2 weeks ago

Phase II Study of Ivonescimab in the Perioperative Setting for Resectable NSCLC Published in Nature Medicine

HONG KONG, Nov. 5, 2026 /PRNewswire/ -- Akeso, Inc. (9926.HK) today announced that results from a Phase II clinical study evaluating its first-in-class PD-1/VEGF bispecific antibod...

Read source
qchron.com /1 week ago

PIMJETMI® (pimicotinib) Developed by Abbisko Therapeutics and Licensed by Merck KGaA, Darmstadt, Germany Receive U.S. FD...

PIMJETMI® (pimicotinib) is a new systemic treatment option for certain U.S. adult patients with symptomatic tenosynovial giant cell tumor (TGCT), demonstrating durable* tumor respo...

Read source
qchron.com /2 weeks ago

Johnson & Johnson announces U.S. FDA Approval of RYBREVANT FASPROâ„¢ (amivantamab and hyaluronidase-lpuj) as First a...

Accelerated approval based on data demonstrating clinically meaningful efficacy, including a 42 percent overall response rate (95 percent confidence interval, 32–52 percent)1

Read source
qchron.com /4 weeks ago

Bio-Thera Announces Promising Clinical Data for BAT8008 in Combination with BAT1308 in First-Line Non-Small Cell Lung Ca...

GUANGZHOU, China, Oct. 24, 2026 /PRNewswire/ -- Bio-Thera Solutions, Ltd. (688177.SH), a commercial-stage biopharmaceutical company developing innovative therapies and biosimilars,...

Read source
healio.com /1 month ago

FDA OKs Lyrfigtu for previously treated bile duct cancer

The FDA approved lirafugratinib — a kinase inhibitor — for adults with previously treated unresectable, locally advanced or metastatic cholangiocarcinoma.The indication for lirafug...

Read source
qchron.com /4 weeks ago

Lilly presents first clinical data in platinum-sensitive ovarian cancer for its investigational, next-generation, FRα-ta...

Sofetabart mipitecan (Sofe-M) in combination with bevacizumab demonstrated a 79% confirmed objective response rate and 100% disease control rate, with similar activity observed acr...

Read source
pharmexec.com /2 weeks ago

<![CDATA[FDA Grants Accelerated Approval to Rybrevant Faspro in Head and Neck Cancer]]>

Read source
healio.com /2 weeks ago

Zanidatamab regimens improve survival for gastroesophageal cancer

First-line zanidatamab-hrii plus chemotherapy, without or with tislelizumab-jsgr, extended survival 24% and 35% vs. trastuzumab plus chemotherapy for those with locally advanced or...

Read source
scmp.com /2 weeks ago

Chinese drug iza-bren doubles lung cancer survival window in phase 3 trial

An anticancer drug developed by Sichuan Biokin Pharmaceutical took centre stage in a late-breaking oral presentation at the European Society for Medical Oncology (ESMO) Congress in...

Read source
qchron.com /1 month ago

ESMO 2026 Preview | Mabwell to Present Clinical Results for Nectin-4-Targeting ADC 9MW2821 in ADC-Pretreated Triple-Nega...

SHANGHAI, Oct. 18, 2026 /PRNewswire/ -- Mabwell (688062.SH, 02493.HK), an innovation-driven biopharmaceutical company with a fully integrated industry chain, will present Phase II...

Read source
biopharmadive.com /1 month ago

Dual-acting drug from AbbVie, Genmab scores in frontline lymphoma trial

The better-than-expected results could make Epkinly the new “undisputed” treatment standard in newly diagnosed DLBCL, according to one analyst.

Read source
qchron.com /4 weeks ago

Positive Overall Survival Results from the Phase III HARMONi-GI1 Trial of Ivonescimab Plus Chemotherapy Versus Durvaluma...

HONG KONG, Oct. 25, 2026 /PRNewswire/ -- Akeso, Inc. (HKEX: 9926.HK) today announced the presentation of results from the randomized, controlled, double-blind, multicenter, registr...

Read source

Turn fresh research into a full content calendar

Use SocialBu to discover ideas, generate post drafts, and schedule them across your social channels.